STRATA Skin Sciences Unveils Study Backing Its Laser Therapy

STRATA Skin Sciences Validates Personalized Medicine Approach
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has recently made headlines with the publication of a groundbreaking study in the field of dermatological treatment. The research, featured in a reputable medical journal, emphasizes the company’s dedication to advancing personalized medicine specifically for psoriasis. By integrating the XTRAC 308nm Excimer Laser with a targeted topical drug, STRATA demonstrates a significant improvement in patient care.
Benefits of XTRAC Excimer Laser Therapy
The published study, reflecting on clinical efficacy, showcases the promising results observed in patients suffering from plaque-type psoriasis—one of the most prevalent forms of the disease. The innovative use of the XTRAC Excimer Laser shows that it can enhance the effects of conventional topical therapies, leading to better patient outcomes.
The Study Overview
This retrospective study included 100 adult patients diagnosed with plaque-type psoriasis. Patients were strategically divided into two groups. The control group received a topical treatment regimen with 0.1% tacrolimus ointment, while the experimental group received the same topical treatment supplemented with phototherapy from the XTRAC Excimer Laser. The laser was applied twice weekly, using personalized dosing based on individual Minimum Erythema Dose (MED).
Outstanding Clinical Findings
The results of the study were compelling. Patients who received the combination treatment showcased a significantly greater reduction in the Psoriasis Area and Severity Index (PASI). The control group saw their mean PASI drop from 18.62 to 5.23, while the observation group experienced a drop from 18.36 to an impressive 3.30. Such results underscore the effectiveness of combining laser therapy with a topical agent, providing critical evidence of its superior efficacy.
Patient Safety and Treatment Personalization
Safety was another cornerstone of interest in the findings. Both treatment avenues reported no instances of serious adverse effects, although mild, self-resolving irritations were observed in a few patients. This emphasizes that the XTRAC Excimer Laser, alongside its topical formulation, is a safe and well-tolerated option for patients seeking effective psoriasis treatment.
The Power of Precision Dermatology
A standout feature of this approach is its personalized nature. The individualized dosing of the excimer laser applies a targeted approach to treatment, minimizing unnecessary exposure to healthy tissue. This principle of precision dermatology is central to improving the patient experience and outcomes. The simultaneous action of the excimer laser and the tacrolimus ointment works to address the underlying causes of psoriasis through complementary mechanisms that enhance patient care.
Expanding STRATA's Impact in Dermatology
Dr. Dolev Rafaeli, STRATA’s President and CEO, eloquently expressed confidence in the findings' implications for future clinical practices. He noted the study strengthens the position of the XTRAC technology in personalized treatment approaches and highlights increasing demand among clinicians for flexible and efficacious treatments in dermatology.
Strategic Benefits and Future Directions
The results not only highlight the potential of the XTRAC laser as a monotherapy but also reinforce the importance of combination strategies in dermatological care. Such findings validate STRATA’s strategic direction and enhance provider confidence in the treatment options available. With over 400 clinical publications supporting excimer therapy, this study serves as further evidence in ongoing discussions to expand reimbursements, navigating a landscape that increasingly favors non-biologic and in-office treatment modalities.
About STRATA Skin Sciences
STRATA Skin Sciences is committed to advancing dermatological care through innovative technology. Their range includes the XTRAC excimer laser, VTRAC lamp systems, and the TheraClear X Acne Therapy System. The company prides itself on its partnership model, enabling collaborative efforts to provide effective treatments while ensuring affordability and accessibility.
Frequently Asked Questions
What is the significance of the new study published by STRATA?
The recently published study shows enhanced patient outcomes when combining XTRAC laser therapy with topical treatment for psoriasis.
How does the combination therapy work?
The XTRAC Excimer Laser targets harmful T-cells and supports the action of tacrolimus, improving the efficacy of psoriasis treatment.
Are there any safety concerns associated with XTRAC therapy?
In the study, no serious adverse effects were reported, indicating that the treatment is generally safe.
What are the benefits of personalized treatment in dermatology?
Personalized treatments allow for targeted strategies that maximize effectiveness and minimize the risk of damaging healthy tissue, which is crucial for conditions like psoriasis.
How does STRATA support healthcare professionals?
STRATA offers a partnership model that includes training, customer service, and marketing support, ensuring healthcare professionals can effectively implement their technologies.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.